Want to see TSE:VPT full AI Analyst Report?
Top Page
VentriPoint Diagnostics
(VPT)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.09
▼(-13.00% Downside)
Action:Reiterated
Date:09/17/26
The score is primarily held back by weak financial durability (negative equity, ongoing losses, and continued cash burn) despite strong revenue growth and very high gross margins. Technicals add further pressure with the stock trading below major moving averages and negative momentum indicators. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Revenue Growth
Strong TTM revenue growth indicates the company is expanding commercial adoption and increasing its revenue base. If sustained, this growth can improve operating leverage, support broader market penetration, and provide a foundation for eventual profitability as the business scales.
Negative Factors
Negative Equity and High Relative Debt
Negative equity signals that accumulated losses have eroded the capital base, while debt materially exceeds the reported asset base. This weak structure reduces financial flexibility, increases dependence on external financing, and leaves less capacity to absorb operating setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong TTM revenue growth indicates the company is expanding commercial adoption and increasing its revenue base. If sustained, this growth can improve operating leverage, support broader market penetration, and provide a foundation for eventual profitability as the business scales.
Read all positive factors
VentriPoint Diagnostics (VPT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$17.36M
Dividend YieldN/A
Average Volume (3M)107.75K
Price to Earnings (P/E)―
Beta (1Y)-0.81
Revenue Growth89.06%
EPS Growth37.62%
CountryCA
Employees10
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.01
Shares Outstanding192,877,940
10 Day Avg. Volume132,323
30 Day Avg. Volume107,750
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VentriPoint Diagnostics Business Overview & Revenue Model
Company Description
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of...
VentriPoint Diagnostics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 147.77K | 179.93K | 95.17K | 49.18K | 68.17K | 0.00 |
| Gross Profit | 132.34K | 118.69K | 95.17K | 42.43K | 57.81K | -48.81K |
| EBITDA | -679.30K | -2.67M | -4.76M | -4.74M | -4.79M | -3.81M |
| Net Income | -2.32M | -3.20M | -4.92M | -4.87M | -4.87M | -3.88M |
Balance Sheet | ||||||
| Total Assets | 611.88K | 472.08K | 658.02K | 1.88M | 5.98M | 9.54M |
| Cash, Cash Equivalents and Short-Term Investments | 333.63K | 55.39K | 60.55K | 1.29M | 5.19M | 9.27M |
| Total Debt | 2.62M | 2.60M | 1.63M | 412.44K | 459.08K | 159.97K |
| Total Liabilities | 4.44M | 4.59M | 3.64M | 1.69M | 1.42M | 1.21M |
| Stockholders Equity | -3.83M | -4.12M | -2.98M | 189.71K | 4.55M | 8.33M |
Cash Flow | ||||||
| Free Cash Flow | -1.92M | -1.55M | -3.39M | -3.80M | -4.14M | -3.15M |
| Operating Cash Flow | -1.92M | -1.55M | -3.39M | -3.80M | -4.14M | -3.15M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.26K |
| Financing Cash Flow | 2.02M | 1.53M | 2.20M | -102.36K | 87.65K | 11.89M |
VentriPoint Diagnostics Technical Analysis
Negative
0.10
Price Trends
0.10
Negative
0.11
Negative
0.11
Negative
Market Momentum
>-0.01
Positive
35.10
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VPT, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.10 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VPT.
VentriPoint Diagnostics Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | C$40.66M | -2.15 | -303.05% | ― | 35.27% | 58.34% | |
48 Neutral | C$289.34M | -6.03 | -62.45% | ― | 59.60% | 32.53% | |
44 Neutral | C$17.36M | -6.87 | 56.40% | ― | 89.06% | 37.62% | |
43 Neutral | C$55.89M | -13.03 | -130.04% | ― | -24.86% | 18.29% |
* General Sector Average
TSE:VPT
VentriPoint Diagnostics
0.09
-0.02
-20.35%
TSE:PINK
Perimeter Medical Imaging AI
0.28
0.03
12.24%
TSE:PRN
Profound Medical
8.18
2.76
50.92%
TSE:TLT
Theralase Technologies
0.19
>-0.01
-2.63%
VentriPoint Diagnostics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Ventripoint Raises Capital and Adds Advisors to Drive VMS+ Commercialization
Positive
Sep 8, 2026
Ventripoint Diagnostics has closed the first tranche of a non-brokered private placement, raising $180,000 toward a planned $350,000 financing to support commercialization of its VMS+™ cardiac imaging platform. The capital will be directed t...
Business Operations and Strategy
Ventripoint and UniDoc Explore Remote AI Cardiac Imaging Collaboration
Positive
Aug 5, 2026
Ventripoint Diagnostics has signed a memorandum of understanding with UniDoc Health to evaluate integrating its AI-enabled VMS+ cardiac imaging platform into UniDoc’s connected-care infrastructure. The collaboration would pair UniDoc’s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.